Suppression of gastric cancer by extract from the tuber of amorphophallus konjac via induction of apoptosis and autophagy

XI CHEN1,2, LIN-QING YUAN1, LIN-JIE LI1, YAO LV1, PEI-FENG CHEN3 and LEI PAN3

1Children’s Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang;
2Key Laboratory of Diagnosis and Treatment of Neonatal Diseases of Zhejiang Province, Hangzhou, Zhejiang;
3The First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, Zhejiang, P.R. China

Received January 13, 2017; Accepted June 8, 2017

DOI: 10.3892/or.2017.5747

Abstract. The tuber of amorphophallus konjac (TuAK) is an antitumor herb used in traditional Chinese medicine. The present study investigated the inhibitory effect of TuAK against gastric cancer and the underlying mechanisms associated with two programmed cell death pathways, apoptosis and autophagy. TuAK was extracted by organic solvents including ethanol and ligarine. The extract of TuAK, shortened as TuAKe, significantly inhibited the growth of cultured gastric cancer cell lines SGC-7901 and AGS, with IC50 of 35-45 µg/ml. TuAKe could increase cell apoptosis and induce cell cycle arrest. For the apoptosis-associated proteins, expressions of survivin and Bcl-2 were decreased by treatment of TuAKe, and the expression of Bax and caspase-9 was increased. Furthermore, TuAKe could promote autophagy, and the antitumor efficacy of TuAKe was significantly hampered by targeted suppression of autophagy, suggesting that autophagy contributed to TuAKe-induced cell death. Furthermore, patients with gastric cancer who received TuAK-based medicinal decoction achieved improved scores in assessment of life quality compared with those without TuAK treatment. This study demonstrated the antitumor activity of TuAK against gastric cancer, and is the first report to show that the underlying mechanism is associated with induction of autophagy. Our data provided support of the clinical use of amorphophallus konjac-based medication in combination with classical chemotherapy to achieve optimized outcome for gastric cancer.

Introduction

Natural compounds from medicinal herbs compose a significant part of first-line antitumor drugs, such as vinca alkaloids, taxans, podophyllotoxin and camptothecins (vincristine, camptothecin and paclitaxel) (1). Since malignant tumors tend to develop chemoresistance, there is high demand for novel antitumor compounds in the clinical practice. Natural herbal medicine has become a promising source for novel discoveries, such as flavonoids (quercetin, silibinin) (2,3), polyphenols (curcumin) (4), alkaloids (berberine) (5), as well as medicinal decoctions containing undefined bioactive ingredients (6).

There are approximately 170 species of amorphophallus worldwide (7), mainly distributed in tropical and subtropical Asia and are used as a food source as well as in traditional Chinese medicine (TCM). The tuber part from a major species of amorphophallus, amorphophallus konjac, locally produced in Zhejiang, China, has been used in the clinical practice of TCM against cancer for decades (8). Reports on the antitumor efficacy of amorphophallus konjac (hereafter referred to as TuAK) can be dated back to the 1990s (9). Recently, an Iranian group has also reported the antitumor effect of amorphophallus konjac tuber using human hepatoma (10,11) and colon cancer (12) models. Thus, TuAK has become an acknowledged source of natural antitumor compounds.

Many antitumor compounds affect apoptosis and autophagy pathways, two major programmed cell death mechanisms (13). Autophagy is featured by delivery of intracellular contents to the lysosome for degradation. On one hand, it serves as an alternative metabolic pathway to provide extra nutrition and energy for cell survival; on the other hand, over-activation of autophagy results in cell death by self-digestion, which has been defined as type II programmed cell death (14). Autophagy-targeting drugs such as chloroquine (CQ) have been applied in clinical trials for highly malignant and resistant tumors (www.clinicaltrials.gov). Thus, autophagy activation is a double-edged sword in tumorigenesis and antitumor therapy, facilitating either cell survival or cell death, depending on the cellular context (15). Some TCM herbs have been found to regulate the level of autophagy (16-18). However, whether they are beneficial or detrimental for the tumor cells is context-dependent and requires detailed investigation under different conditions.
Our group has been investigating the efficacy of TuAK as well as the underlying mechanism for over 10 years in both clinical and laboratory circumstances (19). Recently, we reported the suppression of hepatocellular carcinoma by TuAK extracts both in vitro and in vivo via induction of apoptosis through survivin and Bax (20). In this study, the inhibitory effect of organic solvent-based TuAK extract (shortened as TuAKe) against gastric cancer cells was studied, as well as the underlying mechanisms associated with induction of cell cycle arrest, apoptosis and autophagy. We also report data on a retrospective study on life quality assessment in gastric cancer patients who received TuAK-based decoction while undergoing conventional chemotherapy.

Materials and methods

Reagents and antibodies. TuAK was purchased from Zhejiang Lin-An Medicinal Herbs, Co., Ltd., (Zhejiang, China; Batch no. 061208) and was authenticated by Zhejiang Chinese Medical University. A voucher specimen is maintained in the university. 5-Fluorouracil (5-FU) was from Nantong Jinghua Pharmaceutical Group, Co., Ltd., (Nantong, China). Chloroquine (CQ) was purchased from Sigma-Aldrich (St. Louis, MO, USA). Other chemical reagents (grade AR) were from Sigma-Aldrich, Amresco (Solon, OH, USA) or Aladdin Reagents Co., Ltd. (Shanghai, China). The following antibodies were used: survivin (ZSGB-Bio, Beijing, China), Bax (ZSGB-Bio), Bcl-2 (Santa Cruz Biotechnology, Santa Cruz, CA, USA), caspase-9 (Abcam, Cambridge, MA, USA), LC3 (Sigma-Aldrich), Atg7 (Cell Signaling Technology, Danvers, MA, USA) β-actin (Lianke Bio, Hangzhou, China) and GAPDH (Lianke Bio). The secondary antibodies were conjugated to HRP (Jackson Immunolab, West Grove, PA, USA).

Preparation of TuAK extracts. Dried TuAK was ground to fine particles, soaked in 8x volume of 95% ethanol overnight, and extracted twice by reverse flow, 2 h each time. The ethanol collected was further extracted by 2x volume of ligarine twice. The ligarine extract was recovered and concentrated by distillation in reduced pressure. The concentrated extract was filtered to obtain the organic solvent-based extract. The ethanol residuum was extracted by dH2O twice, 10x volume respectively, and concentrated to obtain the aqueous extract of TuAK. One mega-extraction using 15 kg of TuAK was performed and the extracts obtained were stored as TuAKe.

Eagle’s medium (DMEM; Gibco, Carlsbad, CA, USA). Cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM; Gibco, Carlsbad, CA, USA). Cells were trypsinized and washed by PBS. Aliquots of resuspended cells (5x10⁷/ml) were stained by cell cycle and apoptosis analysis kit (Beckman Coulter, Brea, CA, USA) based on the manufacturer's instructions. FCM analysis was performed immediately afterwards (FACStar™; BD Biosciences, San Jose, CA, USA).

Western blotting. Cells after desired treatment were scraped, spun down, washed by PBS and resuspended in RIPA buffer with standard protease and phosphatase inhibitors. After quantification of protein concentration by BCA method (Lianke Bio), cell lysates were mixed with loading buffer and subjected to SDS-PAGE with 20 μg protein per lane. The proteins were later transferred to PVDF membranes, which were incubated by primary and secondary antibodies. The membranes were developed with an enhanced chemiluminescence kit (Lianke Bio). Each experimental condition was repeated for at least three times. Quantitative analysis of protein levels determined by band intensities was carried out by ImageJ (v1.48u).

Quantitative reverse transcription polymerase chain reaction (qRT-PCR). Total RNA was extracted by TRizol® reagent (Invitrogen, Carlsbad, CA, USA) and reverse transcribed to cDNA by a commercial kit (Takara Bio, Shiga, Japan). Primers for β-actin, BCL2 and BAX were synthesized by Invitrogen (Shanghai, China) with the following sequences: β-actin forward, (5’-ACAACCTTGGATACGTGGAAGAC-3’) and β-actin reverse, (5’-AGGTGGAGGAGTGGGTGTC-3’), BCL2 forward, (5’-ATTGGAGAGTGTGGATCG-3’), BCL2 reverse, (5’-ACCACTTGAAACATGCACGC-3’), BAX forward, (5’-GACACCTGAGCTGACCTGG-3’) and BAX reverse, (5’-GAGGAGATCCAGTGTCAGC-3’). PCR was performed in three independent experiments with multiple repeats (Applied Biosystems StepOnePlus; Applied Biosystems, Foster City, CA, USA) and the products were analyzed by agarose electrophoresis to compare mRNA levels.

Electron microscopy (EM). Cells after treatment were scraped in PBS and spun down. The pellets were fixed by 2.5% glutaraldehyde for one week, then washed by 0.1 M PBS and fixed in 1% osmic acid for 1 h, washed by ddH₂O, dehydrated by serial concentrations of ethanol from 50 to 100%. Then the pellets were dehydrated by 100% acetone, permeated by acetone/resin (1:1, v/v) for 2 h and by pure resin overnight. The resin was polymerized by serial heating at 37, 45 and 60°C, sectioned and stained by uranium acetate-lead citrate, and then observed
Knocking-down the autophagy-related gene ATG7. Cultured cells were infected with lentivirus expressing shRNA targeting ATG7 gene and control scrambled shRNA (Novobio, Shanghai, China) in the presence of polybrene. Twenty-four hours after infection, knocking-down of Atg7 was confirmed by western blotting, and cells were treated by TuAK for another 24 h, with or without CQ for the last 6 h, followed by cell viability assay.

Retrospective cohort study of gastric cancer patients treated by TuAK-based decoction. The institutional ethics committee of Zhejiang Chinese Medical University approved this study and waived the necessity to obtain informed consent based on its nature as a retrospective and observational study. A total of 30 inward gastric cancer patients admitted to the First Affiliated Hospital of Zhejiang Chinese Medical university were grouped into two. Ten patients in the control group received conven - tional chemotherapy using FAM regimen, namely combination of 5-Fu, adriamycin and mitomycin C. Twenty patients in the TuAK group received TuAK-based decoction in addition to the FAM regimen. The evaluated Karnofsky performance status (KPS) scores of all patients were over 60 upon admission to the hospital, and showed no statistically significant difference between the two groups. KPS scores of each patient were re-evaluated after 8 weeks of treatment and compared.

Statistical analysis. Each experiment was performed at least three times with multiple repeats, and the data were analyzed by SPSS (v13.0). The statistical significance was calculated by one-way ANOVA to compare between multiple groups, or by Student’s t-test when only two groups were compared. P<0.05 was considered statistically significant.

Results

The in vitro antitumor activity of TuAK extracts. In cultured human gastric cancer cell lines SGC-7901 and AGS, within 24 h of treatment, the inhibitory effect of the aqueous extract of TuAK was trivial compared with the organic extract, TuAKe (Fig. 1A and B). Based on the inhibition curves, in the two cell lines, the IC50 of TuAKe was 35-45 µg/ml, while the aqueous extract had little inhibitory effect. TuAKe, the more potent extract, was used in the following experiments. In long-term experiments, consecutive treatment of 50 µg/ml TuAKe daily killed ~100% SGC-7901 cells and ~80% of AGS cells within 7 days, while lower dose of TuAKe (30 µg/ml) inhibited ~70% of SGC-7901 cells and 50% of AGS cells (Fig. 1C and D). TuAKe induces cell apoptosis and cell cycle arrest. We analyzed the apoptotic rate in TuAK-treated SGC-7901 cells. In Fig. 2A, FCM was carried out to detect the apoptotic cells induced by TuAKe after co-staining of Annexin V-FITC and PI. After treatment of 24 h, 5-FU induced significant increase of apoptosis; 25 µg/ml TuAKe increased the apoptotic rate but without statistical significance. After cells were treated by 50 or 100 µg/ml TuAKe, cell apoptosis rates were significantly increased (13.3 and 11.2%, respectively) to similar level as the 5-FU-treated group (12.7%).
Cell cycle distribution was analyzed by FCM in SGC-7901 cells treated by TuAKe for 24 h (Fig. 2B). The percentage of cells in the G0/G1 phase increased from 38.5% in the control (PBS) group to 46.6-63.9% in TuAKe-treated groups (25-100 µg/ml); on the other hand, the percentage of cells in the G2/M phase decreased from 31.5% in the control group to 12.5-17.6% in TuAKe-treated groups. Thus, TuAKe treatment resulted in cell cycle arrest in the G0/G1 phase.

TuAKe regulates the expression of apoptosis-associated proteins. To further analyze the molecular evidence of apoptosis, western blottings for several apoptosis-related markers were carried out. Different concentrations of TuAKe could significantly reduce the level of survivin; whereas, there was significant decrease in Bcl-2 as well as increase in Bax and cleaved caspase-9 levels (Fig. 2C and D). By qRT-PCR, it was further demonstrated that TuAKe resulted in decreased BCL2 and increased BAX gene expression (Fig. 2E).

Autophagy induction contributes to TuAKe-induced cell death. Autophagy flux analysis was carried out using HEK293 and AGS cells (Fig. 3A). HEK293, a cell line commonly used in studies on autophagy as a tool, was less sensitive to TuAKe compared with the two gastric cancer cell lines used in this study. The IC50 of TuAKe on HEK293 was higher than the maximum dose tested, 75 µg/ml (Fig. 4B), compared with 35-45 µg/ml in tumor cells (Fig. 1A). As seen in Fig. 3A, in both HEK293 and AGS cells, TuAKe increased the level of LC3-II, the conjugate of cytosolic autophagy-related protein LC3-I with phosphatidylethanolamine (PE), an indicator of either autophagy activation or blockage of autophagic degradation. In the autophagy flux analysis, CQ, the lysosome inhibitor, increased the level of LC3-II; combination of CQ and TuAKe further increased the level of LC3-II, indicating the effect of TuAKe was to promote the formation of LC3-II instead of blocking its degradation, thus, demonstrating induction of autophagy by TuAKe.

The RFP-GFP-LC3 tag is a well-defined tool to monitor the dynamic formation and degradation of LC3-II-positive autophagosomes. Presence of yellow puncta (RFP-GFP-LC3-II) implies autophagosomes. Moreover, because GFP is degraded faster than RFP in the lysosomes, presence of red puncta (RFP only) implies autolysosomes under degradation at the late stage. In both HEK293 and AGS cells stably expressing RFP-GFP-LC3-II, the control cells were free of puncta (Fig. 3B and C), while TuAKe induced significant increase in the number of yellow puncta. Increase in the number of observable autophagosomes further supported induction of autophagy by TuAKe demonstrated by flux analysis (Fig. 3A).
with high electron density, typical of double-membraned autophagosomes (Fig. 3Dc-d). The size of autophagosome-like structures observed under EM was comparable with the LC3-II positive puncta from fluorescent microscopy.

In both HEK293 and AGS cells, after suppression of autophagy by silencing of \textit{ATG7} gene, decrease of \textit{Atg7} and inhibition of autophagy was confirmed by western blotting (Fig. 4A). After targeted suppression of autophagy, the inhibition rate of TuAKe (10-75 µg/ml) on HEK293 cells was significantly decreased from 5-32% in the control group to 2-10% in the siRNA \textit{ATG7} group (Fig. 4B). In AGS cells, decrease of inhibition by TuAKe after \textit{ATG7} knockdown was only significant when TuAKe was used in higher doses (40-50 µg/ml); however, the inhibition rates between the two groups was highly significant with the net difference of 30-40%.

TuAK improves the life quality of gastric cancer patients. We evaluated the KPS scores in 30 gastric cancer patients, 10 received conventional FAM chemotherapeutic regimen and 20 received FAM regimen plus TuAK-based decoction. As shown in Table I, among the 20 patients in the TuAK group, the KPS

<table>
<thead>
<tr>
<th>Group</th>
<th>Improved KPS, n</th>
<th>Stable KPS, n</th>
<th>Decreased KPS, n</th>
<th>Improved or stable KPS, % (n/n)</th>
</tr>
</thead>
<tbody>
<tr>
<td>FAM</td>
<td>1</td>
<td>3</td>
<td>6</td>
<td>40 (4/10)</td>
</tr>
<tr>
<td>FAM+TuAK</td>
<td>10</td>
<td>7</td>
<td>3</td>
<td>85 (17/20)</td>
</tr>
</tbody>
</table>

Comparison of the Karnofsky performance status (KPS) scores in patients undergoing chemotherapy with or without \textit{amorphophallus konjac} tuber (TuAK)-based medicinal decoction. The FAM regimen of chemotherapy was composed of 5-fluorouracil, adriamycin and mitomycin C.
scores in 10 had improved, 7 were stable and 3 were worsened; among the 10 patients from the FAM group, 1 had improved KPS score, 3 were stable and 6 were worsened. More patients in the TuAK group obtained improved or stable KPS scores (85%) compared with those in the FAM only group (40%), suggesting TuAK-based medication could improve the life quality of gastric cancer patients undergoing chemotherapy.

Discussion

Despite of its history in the clinical use and the observable beneficial effects in the field of TCM, the tuber part of *Amorphophallus konjac* is not enlisted in the pharmacopeia and its chemical composition is still poorly studied. As a whole plant, *Amorphophallus konjac* is well tolerated as a food source in some countries. It contains glucomannan (21,22), monosaccharide (23), oligosaccharide (24), polysaccharide (14), aromatic compounds including (+/-)-5,5’-dimethoxysesamin, erythrinasinate, indole-3-carbaldehyde, serotonin, 3,4-dihydroxybenzoic acid, 3,4-dihydroxybenzaldehyde (13,16). The glucomannans are the most studied bioactive components from the powder of *amorphophallus konjac*, and have been registered in clinical trials in adults (25) and in children (25,26) against obesity and diabetes through regulating food absorption in the gut and subsequently decreasing body weight. Glucomannans are typically extracted by water followed by coagulation by ethanol, which produces much higher yields (27) compared with the organic solvents-based isolation methods used in this study.

Theoretically, aquatic extract contains sugar, amino acids, protein and salts; ethanol could extract most active components besides sugar and proteins; while ligarine extract contains lipids, volatile oil, wax, as well as sterides and terpenes (28). Previous reported information on the chemical composition of the organic extract of TuAK is limited; there is only one report in Chinese on 31 chemicals identified by gas chromatography-mass spectrometry (GC-MS) using extraction method similar as ours (29). In our unpublished data, by high pressure liquid chromatography-mass spectrometry (HPLC-MS), up to 71 different chemicals were identified from TuAK, including nitrogen and sulfur-containing compounds. From our data and of others, most chemicals contained in the antitumor TuAK fraction are different species of organic compounds including nitrogen and sulfur-containing compounds. Among the 94 organic compounds identified from whole *amorphophallus konjac* powder, none was found in the list of toxic compounds by the standards of USFDA (30). From out data, the cytoxicity of TuAKe was significantly lower in non-tumor cell line HEK293 compared with gastric cancer cell lines, supporting the previously reported safety of amorphophallus konjac. It is likely that the TuAKe we obtained does not contain cytotoxic compounds; however, further separation and identification of the chemical compositions are to be carried out in future studies using more sophisticated tools such as NMR.

Our data indicated that the organic solvent-based extract, TuAKe, had much stronger antitumor potency compared with the aqueous extract, suggesting ethanol and ligarine based extraction methods to be more appropriate for the purpose of antitumor treatments of TuAK instead of the traditional water-based extraction. The bioactive chemicals are to be identified. However, according to the holistic theory of TCM, it is also likely that the efficacy is due to the combinational use of multiple ingredients.

We found that TuAKe exhibited antitumor effect at relatively low doses, especially in long-term treatment. Induction of apoptosis and cell cycle distribution reached the saturation point when the concentration of TuAKe was >50 µg/ml. Although safe to consume, our data also suggest that TuAK-based medication in relatively smaller doses would be efficient to achieve desired effects.

A TCM decoction contains hundreds of different chemical components and can modulate many molecular targets simultaneously to result in complicated cascades of cellular events. Qing-Yi-Hua-Ji formula, a TuAK-based decoction, was reported to affect multiple downstream targets including...

Figure 4. Autophagy is indispensable in TuAKe-induced cytotoxicity. HEK293 and AGS cells with siRNA targeting ATG7 or scrambled siRNA were treated by TuAKe at indicated concentrations for 24 h. (A) Western blotting of Atg7 and GAPDH (internal control) after targeted siRNA. (B) Inhibition rates were calculated after cell viability assay and data are presented as mean ± SE (n=3). *P<0.05, compared with control siRNA.
Ski (31), Notch 4 and Jagged 1 (32). We have studied how TuAKe regulates cell death pathways. Firstly, TuAKe induced apoptosis by regulation of apoptosis-related proteins including survivin, Bcl-2 and Bax. Survivin belongs to the family of inhibitors of apoptosis proteins (IAP) that regulate cell death by inhibition of caspase activation. It is expressed only in cells in the G2/M phase, but absent in differentiated cells (33,34). Survivin is highly expressed in most human tumors and fetal tissues, and has thus become a biomarker and a therapeutic target in cancer (35). The Bcl-2 family of proteins contain anti-apoptotic proteins including Bcl-2, as well as pro-apoptotic proteins Bax and Bid (36). Decrease of BCL2 and increase of BAX expression was also detected at the mRNA level after TuAKe treatment. Thus, TuAKe could regulate apoptosis through the anti-apoptotic IAP and Bcl-2 family proteins, although was not necessarily dependent on them. Moreover, TuAKe could simultaneously increase the levels of the pro-apoptotic proteins Bax and caspase-9. Furthermore, TuAKe was regulatory on cell cycle distribution. It increased the proportion of cells in the G0/G1 phases and decreased those in the G2/M phases. This result is consistent with decrease of survivin, which is expressed in a cell cycle-dependent manner (33,34). Similar regulatory effect of survivin and Bax by TuAKe was also found in hepatocarcinoma cells in our previous study (20).

In the present study, it was found that activation of autophagy was an indispensable antitumor mechanism of TuAKe. By flux analysis, TuAKe was shown to induce autophagy in both HEK293 and AGS cells. By fluorescent imaging of RFP-GFP-LC3 positive puncta, TuAKe was shown to induce the formation of LC3-II-positive puncta representing the maturing autophagosomes again in both cell lines. Under EM, autophagosome-like double membranated structures with high electron densities, a golden marker for autophagy induction, could be induced by TuAKe (37). Judged by the similar scale in size and numbers, the autophagosome-like structures under EM could be the same structure as the RFP-GFP-LC3-II puncta under fluorescent microscopy. To examine whether activation of autophagy contributed to TuAKe-induced cell death, autophagy was specifically inhibited by knocking-down the expression of ATG7, which functions as an E1-like enzyme to form both LC3-II and the Atg5-Atg12 complex in the autophagosome elongation step, and is required for the canonical autophagy (38,39). Suppression of autophagy by knocking-down of ATG7 significantly reduced the anti-proliferative capacity of TuAKe in both HEK293 and AGS cells, implying an essential role of autophagy activation in the biological events induced by TuAKe.

By our retrospective analysis, TuAK-based decoction exhibited beneficial effects in gastric cancer patients undergoing chemotherapy marked by significantly improved or stable KPS scores. The previously mentioned Qing-Yi-Hua-Ji formula, a decoction with TuAK as one of the major ingredients, has also been reported to increase the survival of late stage pancreatic cancer patients (40). However, the decoction is traditionally prepared on water-based extraction, while our data suggest organic solvents could provide extracts with higher antitumor potency.

In conclusion, based on this study, TuAKe inhibits gastric cancer cells through induction of cell cycle arrest, apoptosis, as well as autophagy. Autophagy is indispensable in the antitumor mechanism of TuAKe. Our findings strongly support the use of TuAK-based medication as an alternative or as a combinational component in conventional treatment regimens against gastric cancer, and support the feasibility to isolate active antitumor compounds from TuAK. The detailed bioactive components and the molecular targets are to be revealed by future studies.

Acknowledgements

The present study is funded by the National Science Foundation of Zhejiang Province, China (no. LY15H160024 to X.C., no. LY16H270006 to L.P) and by the National Science Foundation of China (no. 81202021 to X.C.).

References


